Das, Moupali

Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women

Bekker, L.-G., Das, M., Abdool Karim, Q., Ahmed, K., Batting, J., Brumskine, W., Gill, K., Harkoo, I., Jaggernath, M., Kigozi, G., et al. (2024) · New England Journal of Medicine

HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatment

Cited by 523

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER) primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Mayer, K. H., Molina, J.-M., Thompson, M. A., Anderson, P. L., Mounzer, K. C., De Wet, J. J., DeJesus, E., Jessen, H., Grant, R. M., Ruane, P. J., et al. (2020) · The Lancet

HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatment

Cited by 428

Effect of Risk-Reduction Counseling With Rapid HIV Testing on Risk of Acquiring Sexually Transmitted Infections: The AWARE Randomized Clinical Trial

Metsch, L. R., Feaster, D. J., Gooden, L., Schackman, B. R., Matheson, T., Das, M., Golden, M. R., Huffaker, S., Haynes, L. F., Tross, S., et al. (2013) · JAMA

HIV/AIDS Research and InterventionsHIV, Drug Use, Sexual Risk

Cited by 130